Placebo-controlled, double-blind clinical trials can impede medical progress.
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D001241:Aspirin / Q000627:therapeutic use; D002561:Cerebrovascular Disorders / Q000188:drug therapy; D002986:Clinical Trials as Topic / Q000379:methods*; D004311:Double-Blind Method; D004358:Drug Therapy; D005069:Evaluation Studies as Topic; D006801:Humans; D002546:Ischemic Attack, Transient / Q000188:drug therapy; D009203:Myocardial Infarction / Q000188:drug therapy; D010919:Placebos; D013442:Sulfinpyrazone / Q000627:therapeutic use
D000319:Adrenergic beta-Antagonists; D010919:Placebos; D001241:Aspirin; D013442:Sulfinpyrazone